Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1996

View Archived Issues

Pharmacia & Upjohn, McGill University claim antiparasitic MAb

Novel diagnostic agents for spongiform encephalopathies reported

New calcimimetic agents from ZymoGenetics

Bayer reveals sugar-modified cytostatic agents

New thrombin inhibitors under study at Merck & Co.

Novo Nordisk claims dopamine D3 receptor ligands for CNS indications

VIP analogs and derivatives claimed for smooth muscle relaxation

Therapeutically active NPY analog reported by academic source

Access in-licenses polymer platinum compounds

InSite Vision completes preliminary clinical trial of ophthalmic drug candidate

Dusa photodynamic therapy advances to phase III

Successful phase III results reported for British Biotech PAF antagonist

British Biotech discontinues development of MMP inhibitor

Another British Biotech compound reaches clinical stage

Medarex bispecific antibody enters phase II in colon cancer patients

MGI Pharma acquires drugs from Ilex Oncology

OsmoCyte approved for marketing in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...